Holista Colltech JV Secures Collie Land for New Collagen Facility
Holista Colltech's joint venture Ovicoll has acquired industrial land in Collie to build a modular sheep collagen production plant, aiming for operation by December 2026.
- Ovicoll acquires 3,974 sqm industrial land in Collie for $231,000
- Joint venture with Swang Chai Chuan includes $1.6 million capital injection
- New modular facility replaces previous leased manufacturing site
- Facility expected operational by December 2026
- Holista to provide ongoing updates on construction and milestones
Strategic Land Acquisition for Collagen Production
Holista Colltech Limited (ASX:HCT) has taken a decisive step to boost its collagen manufacturing capacity by acquiring industrial land in Collie, Western Australia. The company's joint venture, Ovicoll Pty Ltd, completed the purchase of a 3,974 square metre site at Lot 2054 Morrison Way for $231,000, settling the deal on 18 June 2026. This acquisition lays the groundwork for a new production facility dedicated to sheep collagen and nano-collagen products.
Transition to Modular, Asset-Light Manufacturing
The land purchase follows Holista's earlier decision to cease leasing its previous manufacturing premises in favour of an asset-light, modular facility model. This shift is designed to enhance operational flexibility and potentially reduce capital expenditure. The new plant is slated to be operational by December 2026, signalling a relatively swift build timeline for the venture.
Joint Venture Backed by Significant Capital Injection
Ovicoll is a joint venture between Holista and Swang Chai Chuan Limited (HKEX:2321), with the latter contributing approximately $1.6 million to the project. This capital injection underscores the partner’s commitment and provides a solid financial foundation for the facility's development. The collaboration aims to leverage Holista's proprietary collagen technologies alongside SCC's investment and expertise.
Implications for Holista’s Growth and Production
Holista’s move into a modular production facility in Collie represents a strategic pivot that could enhance its supply chain and product scalability. The company’s focus on premium, disease-free ovine collagen and nano-collagen aligns with growing global demand for high-quality collagen in health and wellness markets. While details on the facility's capacity and cost structure remain undisclosed, the JV’s formation and land acquisition mark a clear advance in Holista’s production capabilities.
Monitoring Construction Progress and Market Impact
The company has committed to providing updates on construction progress and key milestones as the project unfolds. Investors will be watching how the modular approach translates into operational efficiency and whether the Collie facility can accelerate Holista’s commercialisation of its collagen products. The partnership with SCC, including its sizeable capital commitment, will also be a focal point for assessing the venture’s future prospects.
Bottom Line?
Holista’s Collie facility acquisition signals a tangible step towards scaling its collagen production, but the project's success hinges on timely construction and market uptake of its nano-collagen products.
Questions in the middle?
- What will be the production capacity and cost efficiencies of the new modular facility?
- How will the joint venture with Swang Chai Chuan evolve in terms of ownership and profit sharing?
- What impact will the Collie plant have on Holista’s overall financial performance and market positioning?
